Patients with both MSK and endocrine irAEs had squamous cell carcinoma of the tongue, gastric cancer, and high-grade serous ovarian cancer, and were treated with avelumab in combination with an OX-40 agonist, PD-1 inhibitor, pembrolizumab then nivolumab, and single-agent avelumab, respectively. The gene discussed is TNFRSF4; the disease is tongue squamous cell carcinoma.